摘要:
The present invention relates to novel treatments of mammalian and human heart failure directed at improving cardiac creatine kinase metabolism, the prime energy reserve of cardiac muscle. The invention also relates to novel treatments using gene transfer vectors to increase myocardial creatine kinase protein expression and/or creatine kinase activity, as well as flux through the creatine kinase reaction and to thereby improve cardiac contractile function and ameliorate remodeling in heart failure. The invention further relates to methods for screening and identifying compounds that increase creatine kinase expression and/or creatine kinase activity as potential pharmaceutical compositions for heart failure therapy.
摘要:
Compositions and methods of treating endothelial disorders, including: asthma, erectile dysfunction, pulmonary hypertension, cardiovascular disorders, and other disorders, using a synergistic combination of at least one arginase inhibitor and at least one phosphodiesterase (PDE1), (PDE2) and/or (PDE5) inhibitor are described.
摘要:
The invention features compositions and methods for modulating NOS that are useful for the prevention and treatment of cardiac diseases and disorders, including cardiac hypertrophy and cardiac dilation. In particular, the invention provides compositions comprising tetrahydrobiopterin (BH4), alone or in combination with one or more additional compounds.
摘要:
The instant invention provides methods and compositions for the treatment of cardiac dysfunction. Specifically, the invention provides methods and compositions for modulating Arginase II for the treatment of cardiac dysfunction.